No Data
Stifel Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $48
Stifel analyst Dae Gon Ha maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of 36.2% and a
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Mirum Pharmaceuticals (MIRM) and IDEAYA Biosciences (IDYA)
Cantor Fitzgerald Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $45
Cantor Fitzgerald analyst Joshua Schimmer maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and adjusts the target price from $40 to $45.According to TipRanks data, the analyst has a succe
Reported Saturday, Mirum Pharmaceuticals' LIVMARLI Data Presented At ESPGHAN, Featuring Key Findings On ALGS And PFIC
Presented by Professor Richard J. Thompson, MD, King's College London, United KingdomPatients with PFIC showed significant and sustained improvements in pruritus severity, serum bile acid (sBA) levels
Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting
- Seven abstracts highlighting ALGS and PFIC data, including three oral presentations - Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the highest scoring
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.